DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Herbst RS. et al.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Lancet 2016;
387: 1540-1550
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.